Herbalife LTD. (HLF) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $1.52 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 52.38%. A quarter ago, it was expected that this company would post earnings of $0.87 per share when it actually produced earnings of $0.99, delivering a surprise of 13.79%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.
Herbalife LTD. Shares have lost about 40% since the beginning of the year versus the S&P 500’s decline of -13.6%.
What’s Next for Herbalife LTD.
While Herbalife LTD. Has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Herbalife LTD. Unfavorable. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.81 on $1.3 billion in revenues for the coming quarter and $3.29 on $5.25 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Retail – Pharmacies and Drug Stores is currently in the bottom 16% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
CVS Health (CVS), another stock in the same industry, has yet to report results for the quarter ended June 2022. The results are expected to be released on August 3.
This drugstore chain and pharmacy benefits manager is expected to post quarterly earnings of $2.16 per share in its upcoming report, which represents a year-over-year change of -10.7%. The consensus EPS estimate for the quarter has been revised 2.1% lower over the last 30 days to the current level.
CVS Health’s revenues are expected to be $76.57 billion, up 5.5% from the year-ago quarter.
Zacks’ Top Picks to Cash in on Electric Vehicles
Big money has already been made in the Electric Vehicle (EV) industry. But, the EV revolution has not hit full throttle yet. There is a lot of money to be made as the next push for future technologies ramps up. Zacks’ Special Report reveals 5 picks investors
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.